Evaluate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa.
A legfontosabb adatok
- Ki végzi
- University of Alabama at Birmingham
- Hol
- Birmingham (Egyesült Államok)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Fázis
- Korai 1. fázis
- Résztvevők
- 12 fő, tervezett
- Kezdés
- 2025. máj. 9.
- Várható befejezés
- 2028. júl. 31.
- A vizsgálat típusa
- Beavatkozással járó, 3 csoport
- A vizsgált kezelések
- Siplizumab
- A regiszteradat frissítve
- 2026. szeptember 1.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with moderate to severe hidradenitis suppurativa (HS), a long-term skin disease with painful lumps. Standard treatments have not worked for them. The trial tests siplizumab injections under the skin.
- Életkor
- 18 years and older
- Nem
- Male and female
- A betegség stádiuma
- Moderate to severe HS, Hurley stage II or III, for at least 6 months. It has not responded to conventional therapies. A total AN count (number of abscesses and inflamed lumps) of 5 or more. No more than 20 draining fistulas (draining tunnels under the skin).
- Korábbi kezelés
- At least 1 course of oral antibiotics for HS must have failed, or could not be taken. No biologic drugs or other study drugs in the 3 months before the start. No non-biologic HS treatments, other than antibiotics or hormone therapy, in the 4 weeks before. No new oral antibiotics or hormone therapy in the 6 weeks before. A steady dose of doxycycline or tetracycline for at least 6 weeks is allowed. No kenalog injections into the lesions in the 2 weeks before.
- Biomarker vagy leletérték
- Negative tuberculosis (TB) test (Quantiferon Gold, T-spot) within 3 months before screening. People with past latent TB must be on treatment or have finished it within 5 years. Blood tests must be within set limits, for example platelets of at least 150,000 /μL and hemoglobin of at least 10 g/dL.
A részvétel fő kizáró okai
- Cancer now or in the past 5 years, except treated non-melanoma skin cancer or cervical carcinoma in situ
- Known HIV, hepatitis B or hepatitis C infection
- Pregnancy, breastfeeding, or planning a pregnancy during the study
- Ongoing, chronic or recurrent infections, or a positive SARS-CoV-2 test
- Past allergic reaction to siplizumab or its ingredients
A regiszter feltételei, szó szerint
Mind a 23 feltétel megnézéseKevesebb
Ki vehet részt
- Male or Female at least 18 years of age, and provide informed consent prior to study procedures
- Have moderate to severe HS classified as Hurley stage II or III for at least 6 months refractory to conventional therapies with a total AN count of greater than or equal to 5 prior to enrollment/randomization
- Failed at least 1 course of oral antibiotics for treatment of HS (or demonstrated intolerance to, or had a contraindication to oral antibiotics for treatment of their HS)
- Women of Childbearing potential must have a urine pregnancy test at screening, wk 0 and prior to administration of the study medication
- Women of childbearing potential must be willing to continue a highly effective method of birth control throughout the study (oral, injected or implanted hormonal methods of contraception; placement of an intrauterine device or intrauterine system; barrier methods: condom or occlusive cap (diaphragm or cervical/vault caps) plus spermicidal foam/gel/film/cream/suppository (if available in their locale); male partner sterilization (the vasectomized partner should be the sole partner for that participant); true abstinence (when this is in line with the preferred and usual lifestyle of the participant)
- Negative screening for tuberculosis (TB) (Quantiferon Gold, T-spot) within 3 months prior to screening
- If a positive history of latent tuberculosis:; Currently receiving treatment for latent TB per standard of care; Have documentation of having completed treatment within 5 years prior to baseline
- Agree not to have a live vaccination during the study
Ki nem vehet részt
- Have greater than 20 draining fistulas at screening or Day 1 prior to enrollment/randomization
- Receipt of non-biologic treatments for HS within 4 weeks prior to baseline other than antibiotics or hormonal therapy
- Receipt of biologic agents within 3 months prior to baseline
- Receipt of any other investigational product within 3 months prior to baseline
- Receipt of new oral antibiotics or hormonal therapy within 6 weeks prior to baseline; Subjects may be included if they are on steady dose of doxycycline or tetracycline antibiotics only for at least 6 weeks prior to baseline visit and may not change or discontinue dose during course of study
- Receipt of intralesional kenalog injections within 2 weeks prior to baseline
- Previous hypersensitivity reaction to siplizumab or to any of the components
- Underlying condition (including, but not limited to metabolic, hematologic, renal, hepatic, pulmonary, neurologic, endocrine, cardiac, infectious or gastrointestinal) which in the opinion of the investigator significantly immunocompromises the subject and/or places the subject at unacceptable risk for receiving an immunomodulatory therapy
- Any other active skin disease that in the opinion of the investigator would interfere with the assessment of HS
- Any uncontrolled diagnosis or condition that in the opinion of the investigator will interfere with the assessments or the study
- Currently has a malignancy or a history of a malignancy within 5 years before screen (except successfully treated non-melanoma skin cancer or cervical carcinoma in situ)
- History of an ongoing, chronic or recurrent infectious disease
- Known infection with HIV, hepatitis B or hepatitis C at screening or randomization; Patients who are Hepatitis B Core antibody and/or Hep B Surface Antigen positive will be excluded from this study. Patients who are Hepatitis C ab positive will also be excluded from this study
- Any of the following laboratory abnormalities within 30 days of enrollment:; White blood count (WBC) < 3 x 103/μL;,; CD4+ count below the lower limit of normal,; Platelet count < 150,000 /μL,; Hemoglobin < 10 g/dL,; ALT ≥ 2x upper limit of normal (ULN) or; AST ≥ 2x ULN; Serum creatinine >1.5x ULN in adults; Positive molecular testing of SARS-CoV-2; ALC less than 800 lymphocytes/mm3
- Are currently pregnant, breastfeeding, or planning to get pregnant during the study
Ez a vizsgálat jelenleg itt érhető el: Egyesült Államok.
- University of Alabama at BirminghamBirmingham, Egyesült ÁllamokContact: Ralee' B Bunt, MSPHRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
This study is to investigate the efficacy of siplizumab in the treatment of Hidradenitis Suppurativa.
A vizsgálat 3 csoportja
- siplizumab 10mgA vizsgált kezelés
Up to 6 participants may receive a 10 mg subcutaneous dose of siplizumab from week 0 to week 4 then at weeks 6 and 8.
Kezelés: Siplizumab
- siplizumab 20mgA vizsgált kezelés
Up to 6 participants may receive a 20 mg subcutaneous dose of siplizumab from week 0 to week 4 then at weeks 6 and 8.
Kezelés: Siplizumab
- siplizumab 40mgA vizsgált kezelés
Up to 6 participants may receive a 40 mg subcutaneous dose of siplizumab from week 0 to week 4 then at weeks 6 and 8.
Kezelés: Siplizumab
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- Hivatalos cím
- An Open-label Parallel Group Pilot Study to Demonstrate the Safety and Efficacy of Subcutaneous Siplizumab in the Treatment of Hidradenitis Suppurativa
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. szeptember 1.